Prescriber's Corner

Belinostat for Relapsed or Refractory Peripheral T-Cell Lymphoma

Katelyn Hood, PharmD, and Arpita Shah, PharmD

Nationwide Children's Hospital, Columbus, Ohio, and Georgia Regents Medical Center, The University of Georgia College of Pharmacy, Augusta, Georgia

Katelyn Hood, PharmD,
Nationwide Children's Hospital, 700 Children's Drive, Columbus, OH 43205.
E-mail: katelyn.hood@nationwidechildrens.org

Authors’ disclosures of potential conflicts of interest are found at the end of this article.


J Adv Pract Oncol 2016;7:209–218 | doi: 10.6004/jadpro.2016.7.2.6 | © 2016 Harborside Press®


  

ABSTRACT

The FDA approval of belinostat provides APs with an additional option for heavily pretreated patients with relapsed/refractory peripheral T-cell lymphoma who did not achieve a desirable response to traditional chemotherapy agents. Read about the drug’s mechanism of action, key trials leading to approval, potential adverse events, and important dosing and administration information.




For access to the full length article, please sign in.

Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2016 Harborside Press, LLC All rights reserved.                Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact
Copyright Notice/Disclaimer
Bot trap - Don't go here